Concepedia
Statistics
Publications
22
Citations
4.1K
H-Index
18
Active since
1997
Affiliations
Cyclacel Pharmaceuticals (United Kingdom)(Current)
Memorial Sloan Kettering Cancer Center
Cornell University
Dana-Farber Cancer Institute
The University of Texas MD Anderson Cancer Center
Judy H. Chiao is an author at Cyclacel Pharmaceuticals (United Kingdom) specializing in medicine, pharmacology, and oncology.
Top concepts
MedicinePharmacologyOncologyCancer ResearchCancer TherapyRadiation OncologyPharmacotherapyMolecular OncologyPathologyTumor Biology
Publications per year
1997–2018
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text
Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer
William Kevin Kelly, Owen A. O’Connor, Lee M. Krug et al. · Journal of Clinical Oncology · 2005 · 898 citations · Full text
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Wm. Kevin Kelly, Victoria M. Richon, Owen A. O’Connor et al. · PubMed · 2003 · 623 citations
Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer
J. Zujewski, Ivan D. Horak, C.J. Bol et al. · Journal of Clinical Oncology · 2000 · 265 citations
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul G. Richardson, Constantine Mitsiades, Kathleen Colson et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 191 citations
1–5 of 22